Periostat: profile and news

CollaGenex Pharmaceuticals Reports Financial Results For the First ... May 3, 2006
...$3.7 million compared to approximately $12.0 million in the first quarter of 2005, reflecting significantly reduced sales of Periostat(R) following the ... - Genetic Engineering News,

CollaGenex Posts Wider 1Q Loss May 3, 2006
...said Wednesday that its first-quarter loss widened significantly as generic sales cut heavily into its Periostat gum disease treatment sales. ... - Houston Chronicle,

CollaGenex Pharma Q1 Loss Widens On Lower Sales Due To Generic ... May 3, 2006
...on Wednesday reported first quarter results, posting a net loss that widened from last year on decrease in sales of the company's Periostat drug due to the ... - Trading Markets,

CollaGenex Pharmaceuticals Net Loss Widens In Q1 - Quick Facts May 3, 2006
...totaled $3.7 million compared to $12 million in the prior year quarter, with the company attributing the decline in revenues to the reduced sales of Periostat. ... - Trading Markets,

CollaGenex Pharmaceuticals to Host First Quarter 2006 Earnings ... Apr 26, 2006
CollaGenex also currently sells Periostat, which the Company developed as the first pharmaceutical to treat periodontal disease by inhibiting the enzymes that ... - Genetic Engineering News,

Biotechs have high hopes for ’06 May 4, 2006
The loss reflects reduced sales of the company’s Periostat dental drug since generic competition entered the market a year ago, said CEO Colin Stewart. ... - phillyBurbs.com,

Other information

Indication
For the treatment of the following infections:Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae, Chancroid caused by Haemophilus ducreyi, Uncomplicated gonorrhea caused by Neisseria gonorrhoeae, Respiratory tract infections caused by Mycoplasma pneumoniae or Streptococcus pneumoniae. Lymphogranuloma ve

Pharmacology
Doxycycline, a long-acting tetracycline derived from oxytetracycline, is used to inhibit bacterial protein synthesis and treat non-gonococcal urethritis and cervicitis, exacerbations of bronchitis in patients with COPD, and adult periodontitis.

Mechanism Of Action
Doxycycline, like minocycline, is lipophilic and can pass through the lipid bilayer of bacteria. Doxycycline reversibly binds to the 30 S ribosomal subunits and possibly the 50S ribosomal subunit(s), blocking the binding of aminoacyl tRNA to the mRNA and inhibiting bacterial protein synthesis.

Drug Category
Antimalarials; Anti-bacterial Agents; Tetracyclines; ATC:A01AB22; ATC:J01AA02

Brand Names/Synonyms
Alti-Doxycycline; Apo-Doxy; Atridox; DOXCYCLINE ANHYDROUS; Doryx; Doxy 100; Doxy-Caps; Doxy-Lemmon; Doxychel; Doxychel Hyclate; Doxycin; Doxycycline; Doxycycline Hyclate; Doxycycline Monohydrate; Doxylin; Doxytec; Doxytetracycline; GS-3065; Jenacyclin; Monodox; Novo-Doxylin; Nu-Doxycycline; Periostat; Supracyclin; Vibra-Tabs; Vibramycin

Dosage Forms
Tablet; Capsule; Gel; Liquid; Powder; Powder for Solution

Absorption
completely absorbed after oral administration

Interactions
-->Interactions for Doxycycline:

Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.

Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.

Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.

Absorption of tetracycline is impaired by bismuth subsalicylate.

Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.

The concurrent use of tetracycline and Penthrane (methoxyflurane) has been reported to result in fatal renal toxicity.

Concurrent use of tetracycline may render oral contraceptives less effective.

Drug/Laboratory Test Interactions

False elevations of urinary catecholamine levels may occur due to interference with the fluorescence test.

Chemical IUPAC Name
2-(amino-hydroxy-methylidene)-4-dimethylamino-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione

Chemical Formula
C22H24N2O8

Half Life
18-22 hours

Drug Type
Approved Drug

# Accession No
APRD00597

CAS Registry Number
564-25-0